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cense.Abstract Protein binding affects tissue distribution, plasma clearance and uptake of renal radio-
pharmaceuticals. The 99mTc bound to plasma protein after incubation 99mTc-Gluco-ene-diolate
(99mTc-Sn-Gluco) agent or 99mTc-prylidinomethyl-tetracycline (99mTc-Sn-PMT) agent with plasma
protein. It was observed that the protein bound to 99mTc is lesser extent with (99mTc-Sn-Gluco)
agent than with the 99mTc-PMT agent. 99mTc-Sn-PMT is excreted more rapidly than 99mTc-Sn-
Gluco. On the other hand the percentage binding to protein seems to depend on the origin of
the protein and or the type of protein (human or animal). However lower human protein binding
or higher protein binding were observed with 99mTc-Sn-Gluco or with 99mTc-Sn-PMT, respectively
compared with the binding to rat protein. The unbroken down of the chemical form of the origin of
these two agents and the highest of 99mTc-Sn-Gluco remained as origin in urine indicate that 99mTc-
Sn-Gluco are more stable than 99mTc-Sn-PMT.
Concerning the type of protein binding to 99mTc-Sn-PMT or to 99mTc-Sn-Gluco, it was observed
that Human Plasma Protein is greater binding than Human serum protein or than IgG.
ª 2009 King Saud University. Open access under CC BY-NC-ND license.ity.
lsevier1. Introduction
Several radiopharmaceuticals labeled with 99mTechnetium
have been proposed for renal scintigraphy (Poropat et al.,
1999; Herscheid et al., 1986; Kahn et al., 1994). Among these
are 99mTc-pyrolidinomethyl-tetracycline (99mTc-Sn-PMT)
Zmbova et al., 1983 and 99mTc-Gluco-ene-diolate (99mTc-Sn-
Gluco) Wang et al., 1977. Protein binding is inﬂuenced by
many parameters, such as charge of the agent, the type of pro-
tein, pH, and the amount of the agent in the blood (Dennis
et al., 2000). The in vivo and in vitro measured protein binding
of 99mTechnetium, reﬂects the complex stability of renal agent
(Gano et al., 1989). The in vivo instability of the complex can
140 Y.F. Shaﬁqbe measured the percentage of 99mTc-activity bound to the
protein (Ono et al., 2001). Schumichen et al. (1979) suggested
that the 99mTc-protein-bound is a charged Tc(VI) compound.
99mTc-Sn-PMT (Shaﬁq et al., 1988) and 99mTc-Sn-Gluco (Sha-
ﬁq and AL-Janabi, 1985) are used for static and dynamic
imaging of the kidneys. Signiﬁcant difference was found in
the 99mTc-plasma protein bound of the two complexes. The
data obtained from this study indicate that in vitro 99mTc-plas-
ma protein bound would not inﬂuence the in vivo kinetics. It is
of interest to determine the extent of protein binding of these
radiopharmaceuticals.
2. Materials and methods
The following renal compounds were used in this study: Sn-
PMT and Sn-Gluco kits were obtained from NRC (Nuclear
Research Center, XXXX). The reconstituted compositions
for chromatographic and biodistribution studies were: PMT
lyophilized kit containing 36 mg PMT, 0.55 mg SnC12. Ad-
justed to pH 6.5. Reconstituted in volume of 3 ml of 5 mCi
99mTcO4. Gluco lyophilized kit containing 100 mg D (+) Glu-
cose, 0.150 mg SnC12. Adjusted to pH 7.2. Reconstituted in
volume of 3 ml of 5 m Ci 99mTcO4.
3. Gel Chromatography Column Scanning (GCS)
Gel ﬁltration using Sephadex (AB Pharmacia Fine Chemical,
Sweden) with a Column Scanning technique (GCS) has been
used for studying the chemical state of Technetium in labeled
compounds (Shaﬁq et al., 1990). A column with an inner diam-
eter of 1.5 mm and 330 mm length was ﬁled with swollen
Sephadex G-25 ﬁne to a height of about 300–310 mm. The
sample to be analyzed was applied on the top of the column
in a volume of 0.1–0.3 ml. The sample was developed with
10 ml of 0.9% NaCl. The column was then sealed and scanned
with slit-(1 mm)-collimated NaI(TI) crystal. Reduced hydro-
lyzed 99mTc was found at the top of the column within a zone
of 25 mm, 99mTc-pertechnetate in a zone of 25–60 mm and
99mTc-complexes in a zone of 60–130 mm.4. Evaluation of protein bound and urine excretion
4.1. In vivo plasma protein bound and urine excretion
The degree and the rate of binding in vivo of both kits to pro-
tein were determined as follows: white Wistar male rats (aver-
age weight 180–200 mg) received via intravenous injection (i.v)
of 5 mCi of 99mTc-PMT or 99mTc-Gluco in 0.2 ml. The ratsTable 1 Percent of the 99mTc-activity in plasma and urine of rats at
as obtained from GCS proﬁles.
Time (min) Type of kit 99mTc in plasma
Red. hyd 99mTc 99mTcO4
99mTc comple
10 Tc-Gluco 3.4 ± 0.31 4.6 ± 0.98 36 ± 1.32
60 Tc-Gluco 2.6 ± 0.2 2.4 ± 0.30 29 ± 0.85
10 Tc-PMT 0.8 ± 0.34 4.2 ± 0.12 50 ± 1.15
60 Tc-PMT 3.6 ± 0.23 7.5 ± 1.32 44 ± 0.75
*Data are expressed as (mean ± SD).were sacriﬁced after 1 h by cervical decapitation. Blood and ur-
ine were collected and the blood was centrifuged. 1 ml plasma
of 99mTc-PMT or 99mTc-Gluco complexes bound to plasma
protein. 0.2 ml of plasma protein were applied on the top of
Biogel P6 columns and developed with 10 ml saline. The chem-
ical forms of 99mTc-present in the urine were determined by
chromatography using 0.2 ml of urine and applied on the
top of Biogel P6 column then developed with 10 ml saline.
The column was then sealed and scanned as described above.
4.2. In vitro rat plasma protein binding
In vitro binding of 99mTc-PMT or 99mTc-Gluco to plasma pro-
tein of rat was performed as follows: 10 ml of fresh venous rat
blood was centrifuged and 3 ml of the separated plasma mixed
with 2 ml of 99mTc-PMT or with 2 ml of 99mTc-Gluco and
incubated at different time intervals (5–120 min). Samples of
0.2 ml protein were applied to Biogel P6 column.
4.3. In vitro human protein binding
In vitro binding of 99mTc-Gluco or 99mTc-PMT to Human Ser-
um Albumin (HSA), Human Plasma Protein (HSP) and Hu-
man Immuno Globulin (HIgG) was performed as follows:
10 ml of fresh venous blood of human were centrifuged and
3 ml of; the separated plasma, or HSA (50 mg/ml) or HIgG
(50 mg/ml) were mixed separately with 2 ml of 99mTc-PMT
or with 2 ml of 99mTc-Gluco and incubated at different time
intervals (5–120 min). Samples of 0.2 ml from each mixture
were taken and applied to the top of Biogel P6 column, then
developed with 10 ml saline and scanned as described before.
4.4. Percentage of dose of 99mTc-excreted in faces and urine
Five animals (male White Wistar rats, weighing 180–200 g)
were used for each study. Experimental animals were kept in
special cage to collected faces and urine after i.v injection of
99mTc-PMT or 99mTc-Gluco complexes. In all experiments
about 2.4 mg in 0.2 ml sample of 200 lCi 99mTc of either com-
plexes was given intravenously through the tail vein. Urine and
feaces were collected over the period of 24 h and measured
using a well-type scintillation counter.5. Results and discussion
Most of mixed function chelates like PMT have not been char-
acterized chemically because the radiotracer is not present as a
component (Zmbova et al., 1981). To determine the chemical10 and 60 min after i.v injection of 99mTc-Gluco and 99mTc-PMT
99mTc in urine
x 99mTc-protein bound Red. hyd 99mTcO4
99mTc complex
55.0 ± 0.43
66.0 ± 0.75 1.9 ± 0.01 1.0 ± 0.01 97.0 ± 1.2
45.0 ± 1.40
45.0 ± 0.8 2.7 ± 0.01 10.0 ± 0.1 86.0 ± 1.1
Figure 2 GCS proﬁles show the in vitro 99mTc-plasma protein bound (fraction 21–25) after the incubation of 99mTc-PMT with rat plasma
protein for 10 min, 30 min, 60 min, 90 min and 120 min.
Figure 1 GCS proﬁles show the in vitro 99mTc-plasma protein bound (fraction 11–15 cm) after the incubation of 99mTc-Gluco with rat
plasma protein for 10 min, 30 min, 60 min and 90 min.
Table 2 Percent of 99mTc-radioactivity after various time intervals incubation 99mTc-Gluco and 99mTc-PMT with plasma of rat, as
obtained from GCS proﬁles.
Time (min) Type of kit Non protein bound 99mTc Protein bound 99mTc
Red hyd 99mTc 99mTcO4
99mTc-complex (Plasma rat)
10 Tc-Gluco 1.0 ± 0.32 3.0 ± 0.97 66.0 ± 131 30.0 ± 0.44
30 Tc-Gluco 0.5 ± 0.24 1.5 ± 0.11 68.0 ± 2.16 30.0 ± 0.75
60 Tc-Gluco 0.6 ± 0.21 1.4 ± 1.16 59.0 ± 0.76 39.0 ± 0.80
90 Tc-Gluco 1.0 ± 0.15 2.0 ± 0.72 53.0 ± 0.31 44.0 ± 1.50
10 Tc-PMT 1.7 ± 0.34 1.3 ± 0.48 90.0 ± 0.44 7.0 ± 0.32
30 Tc-PMT 1.5 ± 0.07 5.5 ± 1.31 81.0 ± 0.31 12.0 ± 0.45
60 Tc-PMT 1.8 ± 0.08 6.2 ± 1.62 78.0 ± 0.86 14.0 ± 0.80
90 Tc-PMT 1.5 ± 0.09 4.5 ± 1.63 76.0 ± 0.87 18.0 ± 1.30
*Data are expressed as (mean ± SD).
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were injected with 99mTc-Sn-PMT or 99mTc-Sn-Gluco and
1 ml plasma was analyzed by Gel Column Scanning TechniqueTable 3 Percent of 99mTc-radioactivity after various time intervals
Plasma Protein and human. IgG as obtained from GCS proﬁles.
Time (min) 99mTc-protein binding of 99mTc-Gluco
HAS H. plasma H. IgG
10 7.0 ± 0.33 5.0 ± 0.21 1.1 ± 0
30 7.0 ± 0.40 11.0 ± 0.80 0.5 ± 0
60 7.0 ± 0.03 13.0 ± 1.20 0.7 ± 0
90 7.0 ± 0.52 17.0 ± 1.0 0.7 ± 0
120 9.0 ± 0.10 22.0 ± 1.0 –
*Data are expressed as (mean ± SD).
Figure 3 GCS proﬁles show the in vitro 99mTc-Human Serum Albumi
with HSA for 10 min, 30 min, 60 min, 90 min and 120 min.
Figure 4 GCS proﬁles show the in vitro human immunoglobulin (HI
with HIgG for 10 min, 30 min and 60 min.(GCS). The results of three trials for each protein as assessed
by GCS technique, indicated that 55% of activity of 99mTc
bound to plasma initially, increasing to 66% after 1 h andincubation of 99mTc-Gluco and 99mTc-PMT with HAS, Human
99mTc-protein binding of 99mTc-PMT
HAS H. plasma H. IgG
.05 6.0 ± 0.53 9.5 ± 0.71 2.8 ± 0.07
.02 11.0 ± 0.87 25.0 ± 1.20 2.7 ± 0.06
.04 15.0 ± 1.10 – 2.9 ± 0.05
.03 15.0 ± 0.93 – –
17.0 ± 0.90 – 3.2 ± 0.07
n (HAS) bound (fraction 13–17) after the incubated of 99mTc-PMT
gG) bound (fraction 17–21 cm) after the incubation of 99mTc-PMT
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chelate (99mTc-Sn-Gluco) after injection in the rat. Forty-ﬁve
percentage of the plasma activity remained unchanged at
10 min and 1 h and 86% of urine activity remained as 99mTc-
PMT. This indicates that the 99mTc-protein bound is very
strong and not broken down in vivo (Dennis et al., 2000) (see
Table 1). Although the in vivo distribution of these renal imag-
ing agent (PMT and Gluco) are similar, a number of studies
revealed that signiﬁcant differences in the biokinetics of the
99mTc-renal agent (Schumichen et al., 1979; Shaﬁq et al.,
1988). Difference in protein binding of 99mTc might be respon-
sible for the differences in the biokinetices of the 99mTc-renal
agents. The binding of 99mTc to rat plasma protein fraction
at (11–15 cm, Fig. 1) and (21–25 cm, Fig. 2) after incubation
of the two renal agents namely 99mTc-Gluco and 99mTc-
PMT, respectively with rat plasma in vitro is shown in Table
2. The protein bound of 99mTc was followed for up toFigure 6 GCS proﬁles show the in vitro human immunoglobulin (HIg
with HIgG for 10 min, 30 min and 60 min.
Figure 5 GCS proﬁles show the in vitro 99mTc- Human Serum Album
Gluco with HSA for 10 min, 30 min and 60 min.90 min after incubation. In all cases the protein bound of the
total activity in the plasma fraction are increased with time
after injection, but differed signiﬁcantly in the yield from each
other depending on the renal compound as shown in Fig. 1 and
2. The lowest plasma protein binding with 99mTc of the total
activity in plasma fraction was found in the case of 99mTc-
PMT followed by 99mTc-Gluco. The percentages of in vivo
binding of the two renal agents are greater than the in vitro
binding of rat protein.6. Binding to human protein in vitro
The binding of 99mTc to Human Serum Albumin (HAS), Hu-
man Plasma Protein (HPP) and Human Immunogamma Glob-
ulin (HIgG) is shown in Table 3. The data show signiﬁcant
differences in the degree and rate of binding between the renalG) bound (fraction 13–15 cm) after the incubation of 99mTc-Gluco
in (HAS) bound (fraction 19–23 cm) after the incubated of 99mTc-
Figure 7 Correlation between in vivo and in vitro of plasma
protein bound to 99mTc of rat incubated with 99mTc-Sn-PMT or
with 99mTc-Sn-Gluco as obtained from Gel Column Chromatog-
raphy Scanning.
Figure 8 GCS curves diagram of in vitro verses time of 99mTc-
plasma protein Tc-Human Serum Albumin and Human Immuno
Globulin bound after incubation with Tc-Sn-PMT or with Tc-Sn-
Gloco as obtained from Gel Column Chromatography Scanning.
144 Y.F. Shaﬁqagents and protein. Thus the renal agents do not bind to the
total activity of plasma protein. In all cases the fraction of
the total activity bound to the protein increased with the time
after incubation Figs. 3–6 but differed signiﬁcantly from each
other depending on the renal compound and to the type of
protein. Fig. 7 represented a good correlation between in vivoTable 4 Percentage dose of 99mTc-excreted form at 24 h post intra
amount of 99mTc species.
Renal agents % Inje
Urine
99mTc-PMT 25.4 ±
99mTc-Gluco 37.2 ±
*Data are expressed as (mean ± SD).and in vitro of 99mTc-plasma protein bound of rat, after incu-
bation with 99mTc-PMT or with 99mTc-Gluco, respectively.
The highest plasma protein bound to Tc is found with the incu-
bation with Tc-Sn-Gluco. Fig. 8 show the percentage activity
of Tc-bound to Human Plasma Protein, Human Serum Albu-
min, and IgG are as follow: (1) Higher percentage activity was
found with the incubation PMT than with 99mTc-Gluco of
three kind of protein compare between the two renal agents
Tc-PMT and Tc-Gluco it was found that about 9.5% and
6% of Tc-plasma protein bound in the ﬁrst 30 min increasing
to 25% and 13% by 60 min for the ﬁrst and second agent
respectively, about two times grater. (2) The percentage of
Tc activity bound is less with the incubation with 99mTc-Gluco
than with 99mTc-PMT in case human protein. (3) The curves
show protein bound to Tc goes up from HPP, HAS then H
IgG. The weak binding of Tc-complexes accelerated elimina-
tion rates of radioactivity from blood and non target tissues
due to low binding of Tc-complexes with protein (Ono et al.,
2001). It has been suggested (Schumichen et al., 1979) that pro-
tein binding of 99mTc is due to a charged technetium (V) spe-
cies not further complexes with compound.
During the ﬁrst 24 h after i.v injection of 99mTc-PMT and
99mTc-Gluco in rat the radiopharmaceuticals were not exerted
in large amount in feces (1.9% and 4.6%), but about 25.4%
and 37.2% appeared in urine. However, the percentage of
excretion in urine of 99mTc-Gluco was relatively higher than
that of 99mTc-PMT as shown in Table 4. Analysis of urine of
two complexes isolated from bladder by GCS, show that
86% and 97% of the technetium activity was still as 99mTc-
PMT and 99mTc-Gluco. The remaining % was 99mTcO4.
7. Conclusion
Notable features of these results are as follows: (1) Both com-
plexes do not bound to plasma protein. (2) Signiﬁcant differ-
ence was found in plasma protein bound to 99mTc of two
complexes in rats and in human. (3) The percentage activity
of 99mTc-bound to plasma protein are as follow; (1) higher per-
centage activity was found with the incubation 99mTc-Gluco
than with 99mTc-PMT of rat protein, whereas the percentage
of the activity are less with the incubation with 99mTc-Gluco
than with 99mTc-PMT in case human protein. (4) The percent-
ages of in vivo binding of the two renal agents are greater than
the in vitro binding of rat protein. (5) The percentage of Tc
activity bound is less with the incubation with 99mTc-Gluco
than with 99mTc-PMT in case human protein. The curves show
protein bound to Tc goes up from HPP, HAS then H IgG. (6)
The successive increase in the amount of protein bound to Tc,
probably inﬂuence the kidney uptake, which is in agreement
with that found by Ono et al. (2001) and Schumichen et al.
(1979).venous injection of 99mTc-PMT or 99mTc-Gluco and the relative
cted dose
Feces
0.95 1.9 ± 0.02
1.01 4.6 ± 0.0
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